Logo image of 22UA.DE

BIONTECH SE-ADR (22UA.DE) Stock Fundamental Analysis

Europe - FRA:22UA - US09075V1026 - ADR

89.7 EUR
-1.05 (-1.16%)
Last: 10/17/2025, 7:00:00 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to 22UA. 22UA was compared to 81 industry peers in the Biotechnology industry. 22UA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. 22UA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

3

1. Profitability

1.1 Basic Checks

22UA had negative earnings in the past year.
22UA had a negative operating cash flow in the past year.
22UA had positive earnings in 4 of the past 5 years.
22UA had a positive operating cash flow in 4 of the past 5 years.
22UA.DE Yearly Net Income VS EBIT VS OCF VS FCF22UA.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B

1.2 Ratios

The Return On Assets of 22UA (-1.60%) is better than 69.14% of its industry peers.
Looking at the Return On Equity, with a value of -1.87%, 22UA is in the better half of the industry, outperforming 75.31% of the companies in the same industry.
Industry RankSector Rank
ROA -1.6%
ROE -1.87%
ROIC N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
22UA.DE Yearly ROA, ROE, ROIC22UA.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 50 100 150

1.3 Margins

22UA has a better Gross Margin (84.15%) than 75.31% of its industry peers.
22UA's Gross Margin has been stable in the last couple of years.
22UA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 84.15%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
22UA.DE Yearly Profit, Operating, Gross Margins22UA.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150

More info and screens

5

2. Health

2.1 Basic Checks

22UA does not have a ROIC to compare to the WACC, probably because it is not profitable.
22UA has more shares outstanding than it did 1 year ago.
22UA has more shares outstanding than it did 5 years ago.
The debt/assets ratio for 22UA is higher compared to a year ago.
22UA.DE Yearly Shares Outstanding22UA.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M
22UA.DE Yearly Total Debt VS Total Assets22UA.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

2.2 Solvency

An Altman-Z score of 6.11 indicates that 22UA is not in any danger for bankruptcy at the moment.
22UA has a better Altman-Z score (6.11) than 79.01% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that 22UA is not too dependend on debt financing.
22UA's Debt to Equity ratio of 0.01 is fine compared to the rest of the industry. 22UA outperforms 77.78% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 6.11
ROIC/WACCN/A
WACC7.28%
22UA.DE Yearly LT Debt VS Equity VS FCF22UA.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 5B 10B 15B 20B

2.3 Liquidity

A Current Ratio of 8.61 indicates that 22UA has no problem at all paying its short term obligations.
22UA has a Current ratio of 8.61. This is amongst the best in the industry. 22UA outperforms 90.12% of its industry peers.
A Quick Ratio of 8.48 indicates that 22UA has no problem at all paying its short term obligations.
The Quick ratio of 22UA (8.48) is better than 88.89% of its industry peers.
Industry RankSector Rank
Current Ratio 8.61
Quick Ratio 8.48
22UA.DE Yearly Current Assets VS Current Liabilites22UA.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 31.43% over the past year.
22UA shows a small growth in Revenue. In the last year, the Revenue has grown by 6.99%.
The Revenue has been growing by 90.73% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
Revenue 1Y (TTM)6.99%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%102.64%

3.2 Future

The Earnings Per Share is expected to grow by 14.18% on average over the next years. This is quite good.
Based on estimates for the next years, 22UA will show a small growth in Revenue. The Revenue will grow by 3.47% on average per year.
EPS Next Y-78.2%
EPS Next 2Y-19.29%
EPS Next 3Y-12.82%
EPS Next 5Y14.18%
Revenue Next Year-18.22%
Revenue Next 2Y-3.87%
Revenue Next 3Y-1.25%
Revenue Next 5Y3.47%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
22UA.DE Yearly Revenue VS Estimates22UA.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
22UA.DE Yearly EPS VS Estimates22UA.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

22UA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year 22UA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
22UA.DE Price Earnings VS Forward Price Earnings22UA.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60 -60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
22UA.DE Per share data22UA.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

A cheap valuation may be justified as 22UA's earnings are expected to decrease with -12.82% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-19.29%
EPS Next 3Y-12.82%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for 22UA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONTECH SE-ADR

FRA:22UA (10/17/2025, 7:00:00 PM)

89.7

-1.05 (-1.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-04 2025-08-04/bmo
Earnings (Next)N/A N/A
Inst Owners23.44%
Inst Owner ChangeN/A
Ins Owners2.11%
Ins Owner ChangeN/A
Market Cap21.56B
Analysts80
Price Target118.49 (32.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)27.65%
Min EPS beat(2)18.78%
Max EPS beat(2)36.51%
EPS beat(4)4
Avg EPS beat(4)107.89%
Min EPS beat(4)18.78%
Max EPS beat(4)225.36%
EPS beat(8)5
Avg EPS beat(8)138.73%
EPS beat(12)9
Avg EPS beat(12)208.98%
EPS beat(16)12
Avg EPS beat(16)163.75%
Revenue beat(2)2
Avg Revenue beat(2)36.39%
Min Revenue beat(2)1.02%
Max Revenue beat(2)71.75%
Revenue beat(4)4
Avg Revenue beat(4)46.83%
Min Revenue beat(4)1.02%
Max Revenue beat(4)107.62%
Revenue beat(8)4
Avg Revenue beat(8)11.78%
Revenue beat(12)6
Avg Revenue beat(12)6.28%
Revenue beat(16)9
Avg Revenue beat(16)9.6%
PT rev (1m)4.35%
PT rev (3m)-0.4%
EPS NQ rev (1m)-7.89%
EPS NQ rev (3m)28.66%
EPS NY rev (1m)1.16%
EPS NY rev (3m)6.5%
Revenue NQ rev (1m)3.19%
Revenue NQ rev (3m)18.05%
Revenue NY rev (1m)1.75%
Revenue NY rev (3m)4.99%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.49
P/FCF N/A
P/OCF N/A
P/B 1.17
P/tB 1.29
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-3.96
Fwd EYN/A
FCF(TTM)-10.64
FCFYN/A
OCF(TTM)-7.22
OCFYN/A
SpS11.98
BVpS76.98
TBVpS69.28
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -1.6%
ROE -1.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 84.15%
FCFM N/A
ROA(3y)13.87%
ROA(5y)21.46%
ROE(3y)16.07%
ROE(5y)27.17%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.1%
GM growth 5Y0.34%
F-Score3
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 270.61%
Cap/Sales 28.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.61
Quick Ratio 8.48
Altman-Z 6.11
F-Score3
WACC7.28%
ROIC/WACCN/A
Cap/Depr(3y)277.19%
Cap/Depr(5y)250.97%
Cap/Sales(3y)12.34%
Cap/Sales(5y)11.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.38%
EPS Next Y-78.2%
EPS Next 2Y-19.29%
EPS Next 3Y-12.82%
EPS Next 5Y14.18%
Revenue 1Y (TTM)6.99%
Revenue growth 3Y-47.47%
Revenue growth 5Y90.73%
Sales Q2Q%102.64%
Revenue Next Year-18.22%
Revenue Next 2Y-3.87%
Revenue Next 3Y-1.25%
Revenue Next 5Y3.47%
EBIT growth 1Y-1.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-0.41%
EBIT Next 3Y5.33%
EBIT Next 5Y19.83%
FCF growth 1Y-129.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-118.63%
OCF growth 3Y-38.43%
OCF growth 5YN/A